Effects of oral sildenafil citrate (Viagra) on heart rate variability

Amaç: Sildenafil süratin kalp hızı değişkenliği üzerine etkilerini incelemek, malign aritmi ve ani kardiyak ölümlere yol açıp açmadığını araştırmaktır. Materyal ve Metod: Erektil disfonksiyonu olan 50 hasta çalışmaya alındı. Hastalara sildenafil sitrat tedavisi öncesi ve tedavi sırasında holter monitörizasyonu ile kalp hızı değişkenliği değerleri tesbit edildi. Ortalama 3 ay süresince takip edilen hastalara cinsel ilişkiden 1 saat önce ve günde maksimum 1 kez olmak üzere 50 mg sildenafil sitrat kullanmaları önerildi. 3 ay sonra kontrol hoher monitörizasyonundan 4 gün önceden başlayarak yükleme amacıyla 50 mg/gün sildenafil sitrat kullandırıldı. 4. günün sabahı holter moniterizasyonuna başlanınca ilaç kullandırıldı ve holler sonucunu etkilememesi için 24 saat boyunca cinsel ilişki yasaklandı. 24 saat süreyle kalp hızı değişkenliği değerleri tesbit edildi. Bulgular: 24 saatlik elektrokardiyografi (EKO) kaydındaki tüm normal R-R aralıklarının standart sapması anlamına gelen ve sempatik aktivasyönun göstergesi olan SDNN'nin kontrolü, baseline değeri ile karşılaştırıldığında anlamlı bulunmadı. Tedavi sırasındaki balans (LF/HF) değeri anlamlı olarak düşük bulundu (p

Sildenafil sitratin kalp hızı değişkenliği üzerine etkisi

Purpose: To investigate the effects of sildenafil citrate (Viagra) on heart rate variability and to find whether sildenafil citrate is a probable cause of lethal arrhythmias and sudden cardiac death Methods: 50 patients with erectile dysfunction were evaluated with Hoher monitorisation and the heart rate variability was determined over a period before and during oral sildenafil citrate therapy. Patients have taken 50-mg sildenafil citrate one hour before sexual activity for 3 months. After 3 months patients used 50-mg/day-sildenafü citrate for four days before control holler monitorisation. All heart rate variability parameters, such as the standard deviation of the normal -to-normal (NN) intervals (SDNN), the standard deviation of the 5- min average ofNN intervals (SDANN), the square root of squared successive differences in NN intervals (r-MSSD), the percentage ofNN intervals with a cyclic length over 50 ms different from the previous interval (pNNSO), in the time domains studied during 24 hours. Frequency domains such as low frequency (LF) showing sympathetic activity, high frequency (HF) showing parasympathetic activity, and total power (LF/HF ratio) values showing parasympathetic activity were studied during 24 hours. Results: SDNN values were not found to be significant when compared with the baseline SDNN. pNN50 was found to be statistically significant when compared with the baseline pNN50 (p

PDF

___

1. Feldmann HA, Goldstein I, Hatzichristou DG, Krane RJ,and McKinley JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
2. Rajfer J, Aronson WJ, Bush PA, Doery FJ, Ignarro LJ.Nitric oxide as a mediator of relaxation of the corpus cavemosum in response to nonadrenergic, noncholinergic neurotrahsmission. N Engl. J Med. 1992; 326: 90-94.
3. Burnett AL. The role of nitric oxide in the physiology of erection. Biol. Reprod 1995; 52: 485-489.
4. Padma-Nathan N, Steers WD, Wicker PA. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group. Int J Clin Pract. 1998; 52:375-379.
5. A Morales, C Gingell, M Collins, PA Wicker and IH Osterloh. Clinical safety of oral sildenafil citrate in the treatment of erectile dysfunction. Int.. J Impot Res. 1998;10: 69-74.
6. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil Citrate on Human Hemodynamics. Am J Cardiol 1999; 83: 13-20.
7. Conti CR, Pepine CJ, Sweeney M. Efficacy and Safety of Sildenafil Citrate in the Treatment of Erectile Dysfunction In-Patients with Ishemic Heart Disease. Am J Cardiol 1999; 83: 29-34.
8. Karasan K, Molgoard H, Wikstrand J, Sjöström L. Heart rate variability in obesity and effect of weight loss. Am J.Cardiol, 1999; 83: 1242-1247.
9. Cowan MJ, Pike K, Burr RL. Effects of gender and age on heart rate variability in healthy individuals and in persons after sudden cardiac arrest. J Electrocardiol 1994;27 (Supp): 1-9.
10. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
11. Greenstein A, Chen J, Miller H, Matzkin H, Villa Ybraf Z. Does severity of ischemic disease correlate with erectile function? Int. J Impot Res. 1997; 9: 123-126.
12. Muller JE, Mittleman A, Maclure M, Sherwood JB, Tofler GH. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. JAMA 1996; 275:1405-1409.
13. Webb DJ^ Boolell M, Muirhead G. Cardiovascular effects of phophodiesterase type 5 inhibition with concomitant nitrate therapy. (Abstr.) Circulation 1998; 98 (suppl 17):637.
14. Carisi A.P, Rohde L.E.P, Ruy SM, Ferlin EL, Leite C,Ribeiro JP. Sympathetic nervous system representation in time and frequency domain indices of heart rate variability. Eur J Appl Physiol 1998; 79: 69-73.
15. Katona PG, Jih F. Respiratory sinus arrhythmia: noninvasive measure of parasympathetic cardiac control. J.Appl Physiol 1975; 39: 801-805.
16. Hayano J, Skakibara Y, Yamada A. Accuracy of assessment of cardiac vagal tone by heart rate variability in normal subjects. Am J Cardiol 1991; 67: 199-204.
17. Akselrod S, Gordon D, Ubel FA, Shannon DC, Barger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuations: A quantitative probe of beat-to-beat cardiovascular control. Science 1981; 213: 220-222.
18. Pagani M, Furlan R, Pizzinelli P, Crivellaro W, Cerutti S,Malliani A. Spectral analysis of R-R and arterial pressure variability's to assess sympatho- vagal interaction during mental stress in humans. J Hypertens 1989; 7( Suppl): 14-15.
19. Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R,Pizzinelli P, Sandrone G, Malfatto G, Dell'Orto S,Piccaluga E, Turiel M, Baselli G, Cerutti S, Malliani A.Power spectral analysis of heart rate and arterial pressure variabities as a marker of sympatho- vagal interaction in man and conscious dog. Circ Res 1986; 59: 178-193.
20. Rimoldi O, Pierini S, Ferrari A, Cerrutti S, Pagani M,Malliani A: Analysis of the short -term oscillations of RR and arterial pressure in conscious dogs. Am J Physiol 1990; 258: 967-976.
21. Malliani A, Pagani M, Lombardi F, Cerutti S. Cardiovascular neural regulation explored in the frequency domain. Circulation 1991; 84: 1482-1492.
22. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post myocardial infarction risk stratification. Circulation 1992; 85 (Suppl 1): 177-191.
23. Zusman RM, Morales A, Glasser DB, and Osterloh IH. Overall Cardiovascular Profile of Sildenafil Citrate. Am J Cardiol 1999; 83 (5A) : 35-44.
24. Drory Y, Shapira I, Fishman EZ, Pines A. Myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol 1995; 75: 835-837.